Study to evaluate the effectiveness and safety of drug- oral tofacitinib in patients with Parthenium dermatitis
- Conditions
- Health Condition 1: L237- Allergic contact dermatitis due toplants, except food
- Registration Number
- CTRI/2023/10/058514
- Lead Sponsor
- AIIMS, New Delhi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Patients with airborne contact dermatitis with positive patch test to Parthenium, having a Parthenium Dermatitis Severity Score (PDSS) of more than or equal to 10.
2. Patients more than or equal to 18 years of age.
3. Consenting patients who are willing to undergo treatment and report for follow up.
1. Patients with significant and active liver, renal or haematological disease.
2. Patients < 18 years of age.
3. Pregnant and lactating females.
4. Patients with active or latent TB.
5. Patients with a lymphocyte count less than 500 cells/mm3, an absolute neutrophil count less than 1000 cells/mm3, or hemoglobin level less than 9 g/dL.
6. Patients with active infections.
7. Patients with history of thromboembolic phenomenon or on anticoagulants
8. Patients on immunosuppressive therapy in the last 4 weeks.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method